Prescient Therapeutics

Last updated

Prescient Therapeutics Ltd is a clinical stage oncology company. The company is focused on the development of a universal CAR-T platform (OmniCAR), enhanced CAR-T cell manufacturing & function (CellPryme) and on two small molecule drug targeted therapies (PTX-100 & PTX-200).

Contents

Prescient Therapeutics Ltd
Company type Public
ASX:  PTX
Industry Biotechnology
Founded2014
Headquarters Melbourne, Australia
Key people
Steven Yatomi-Clarke
(CEO and Managing Director)
Rebecca Lim
(Senior VP Scientific Affairs)
Dan Shelly
(VP Business Development & Alliances)
Steve Engle
(Non-executive chairman)
ProductsOmniCAR, CellPryme, PTX-200, PTX-100
Website www.ptxtherapeutics.com

History

Prescient Therapeutics Ltd (Prescient) was created in 2014 by bringing together two small molecule drug assets from separate US private companies (Pathway Oncology for PTX-100 and AKTivate Therapeutics for PTX-200) into the existing ASX-listed company Virax Holdings Ltd (Virax).

Virax had been previously unsuccessful in developing a viral delivery of immunologic genes for the treatment of HIV. Paul Hopper, an Australian bio-entrepreneur, looking to access public markets to help develop the PTX-100 & PTX-200 assets, helped coordinate sequential reverse takeovers wherein Virax first acquired Pathway Oncology (deal announced 17 March 2014, [1] completed 30 May 2014 [2] ) and then AKTivate Therapeutics (deal announced 17 October 2014, [3] completed 11 December 2014 [4] ). Virax then changed its name to Prescient Therapeutics in December 2014. [5]

Prescient expanded its focus into cellular therapies in 2019, [6] and in May 2020 announced the development of its universal immune receptor platform OmniCAR from technologies developed at University of Pennsylvania (Penn) and Oxford University. [7]

OmniCAR

OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. [8]

Prescient developed the OmniCAR platform by combining a universal immune receptor technology invented at University of Pennsylvania (Penn) by Dr. Daniel J. Powell, Jr. and Dr. Andrew Tsourkas, with a molecular binding system (termed SpyTag/SpyCatcher) licensed from the University of Oxford, together with other Prescient proprietary technologies.

The resultant modular CAR system, named OmniCAR, decouples antigen recognition from the T-cell signalling domain. The targeting ligand can then be administered and titrated separately to the CAR-T cells thereby creating on-demand and controllable T-cell activity post infusion. This separation of the ligand dosing provides potential safety advantages through increased control of the resultant CAR activation throughout the therapy, as well as ability to target multiple antigens, either simultaneously or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time. Prescient notes this may assist in overcoming T-cell exhaustion and persistence, and these features collectively provide potential advantages in solid tumours which are characterised by antigen heterogeneity, antigen escape and a hostile tumour microenvironment. [9]

Prescient’s initial focus for OmniCAR is CAR-T for oncology. However, the OmniCAR platform can be applied to any immune cell type (including T-cells, NK cells, Macrophages) and combine with any target binding ligand (scFv, Antibody, Aptamers, Labels for imaging) [8] enabling a potential modular approach applicable to the broader field of cell therapies. OmniCAR is relevant for both autologous or allogeneic approaches.

OmniCAR Internal Programs

In January 2021 Prescient named three internal clinical programs it would pursue using the OmniCAR platform: [10]

The programs are all currently in preclinical development.

In September 2022 Prescient entered a strategic collaboration with the MD Anderson Cancer Center (MD Anderson) to create OmniCAR T cells armed with an undisclosed novel binder with the aim of creating best-in-class cellular immunotherapies for blood cancers. Prescient described the binders as "T cell receptor (TCR)-like antibodies" which are expected to be both highly specific and will enable the targeting of proteins on the inside of a tumour cell. [11] The initial focus of the collaboration is in AML, combining the novel binder from MD Anderson with Prescient’s existing CD33 & CLL-1 binders.

OmniCAR Preclinical Milestones

Prescient has entered a collaboration agreement with Peter MacCallum Cancer Centre (Peter Mac), one of the world leaders in CAR-T research and manufacturing, to develop the OmniCAR technology. [12]

Since announcing the OmniCAR platform in May 2020 Prescient has released results of several preclinical milestones;

In August 2022 Prescient announced a manufacturing services agreement with Q-Gen Cell Therapeutics who will produce its OmniCAR cell lines for Prescient’s in-house clinical trials. [15]

Cell Therapy Enhancements

CellPryme-M

CellPryme-M, developed by Prescient in partnership with Peter Mac, was announced in June 2022 as a cell therapy enhancement platform technology that produces superior cells during the cell manufacturing process. [16] During a single, rapid step during manufacturing, cells are pushed toward phenotypes with favourable characteristics for CAR-T including more central memory T-cells, more CD4+ helper cells, cells with more chemokine receptors and greater genomic stability. In pre-clinical trials Prescient demonstrated cells produced by CellPryme-M are less prone to exhaustion, enabling longer duration of cancer killing activity, and are capable of improved tumour trafficking and penetrance compared to the current generation of CAR-T cells. Resultantly, CellPryme-M CAR-T cells performed significantly better than conventional CAR-T cells in highly aggressive solid cancer models. [17]

CellPryme-A

CellPryme-A, developed by Prescient in partnership with Peter Mac, was announced in September 2022 as an adjuvant / neoadjuvant therapy designed to be administered intravenously to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. In preclinical studies using a solid tumour murine model (HER2+ MC38 colon carcinoma) CellPryme-A significantly decreased suppressive regulatory T cells; increased expansion of CAR-T cells in vivo; increased tumour penetration of CAR-T cells. CellPryme-A significantly improved both tumour killing and host survival and the effects were magnified when CellPryme-A was used in conjunction with CellPryme-M. [18] [19]

Prescient intends to use both its CellPryme-M and CellPryme-A technologies for its own OmniCAR programs in addition to offering it to other companies under licence to enhance their respective cell therapy products.

PTX-200

PTX-200, Triciribine Phosphate Monohydrate, is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast cancer and ovarian cancer, as well as leukaemia. PTX-200 was invented by Professor Said Sebti at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida.

PTX-200 is currently in a Phase 1b/2 trial in relapsed and refractory Acute Myeloid Leukemia (AML), where it has resulted in 4 complete remissions so far. [20] The AML study is led by world-renowned leukemia expert Professor Jeffrey Lancet at the H. Lee Moffitt Cancer Center in Florida. PTX-200 has Orphan drug designation in AML from the FDA due to the current poor outcomes associated with the disease and relative lack of effective treatment options. [21]

PTX-200 also previously generated encouraging Phase 2a data in HER2-negative breast cancer [22] and Phase 1b in recurrent or persistent platinum resistant ovarian cancer. [23]

PTX-100

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1(GGT-1). This enzyme, by posttranslationally modifying the small GTPase Rho with isoprenoid lipids, plays a role in malignant transformation of cells and the inhibition of apoptosis. PTX-100 disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is licensed by Prescient from Yale University, and was invented by Prescient Chief Scientific Officer, Professor Said Sebti, and Professor Andrew Hamilton.

PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of haematological and solid malignancies. [24] PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it has shown encouraging efficacy signals and safety. [24] The lead investigator on the study is Professor Miles Prince, AM.

PTX-100 was granted Orphan Drug Designation for the treatment of peripheral T-cell lymphomas (PTCL). [25] Prescient has also obtained notice of allowance for a US patent covering the use of a companion diagnostic for stratifying patients most likely to respond to PTX-100 therapy. [26]

Related Research Articles

<span class="mw-page-title-main">Trastuzumab</span> Medication

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.

A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.

<span class="mw-page-title-main">Cancer immunotherapy</span> Artificial stimulation of the immune system to treat cancer

Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.

An oncoantigen is a surface or soluble tumor antigen that supports tumor growth. A major problem of cancer immunotherapy is the selection of tumor cell variants that escape immune recognition. The notion of oncoantigen was set forth in the context of cancer immunoprevention to define a class of persistent tumor antigens not prone to escape from immune recognition.

<span class="mw-page-title-main">Bi-specific T-cell engager</span> Class of artificial monoclonal antibodies

Bi-specific T-cell engagers (BiTEs) are a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs. They direct a host's immune system, more specifically the T cells' cytotoxic activity, against cancer cells. BiTE is a registered trademark of Micromet AG.

<span class="mw-page-title-main">Vadimezan</span> Chemical compound

Vadimezan is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression.

<span class="mw-page-title-main">Phosphoinositide 3-kinase inhibitor</span>

Phosphoinositide 3-kinase inhibitors are a class of medical drugs that are mainly used to treat advanced cancers. They function by inhibiting one or more of the phosphoinositide 3-kinase (PI3K) enzymes, which are part of the PI3K/AKT/mTOR pathway. This signal pathway regulates cellular functions such as growth and survival. It is strictly regulated in healthy cells, but is always active in many cancer cells, allowing the cancer cells to better survive and multiply. PI3K inhibitors block the PI3K/AKT/mTOR pathway and thus slow down cancer growth. They are examples of a targeted therapy. While PI3K inhibitors are an effective treatment, they can have very severe side effects and are therefore only used if other treatments have failed or are not suitable.

<span class="mw-page-title-main">ALK inhibitor</span>

ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. They fall under the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of tumour cells. All the current approved ALK inhibitors function by binding to the ATP pocket of the abnormal ALK protein, blocking its access to energy and deactivating it. A majority of ALK-rearranged NSCLC harbour the EML4-ALK fusion, although as of 2020, over 92 fusion partners have been discovered in ALK+ NSCLC. For each fusion partner, there can be several fusion variants depending on the position the two genes were fused at, and this may have implications on the response of the tumour and prognosis of the patient.

Neuvenge, Lapuleucel-T, is a therapeutic cancer vaccine (TCV) in development by Dendreon (DNDN). It uses the "immunotherapy platform approach" first successfully demonstrated on the U.S. Food and Drug Administration (FDA)-approved TCV Provenge. It was first tested on breast cancer patients with tumors expressing HER2/neu, and is now scheduled to be tested on bladder cancer patients.

<span class="mw-page-title-main">Cellectis</span> French biopharmaceutical company

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

Kite Pharma is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.

<span class="mw-page-title-main">Immutep</span>

Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.

<span class="mw-page-title-main">Juno Therapeutics</span> American biopharmaceutical company

Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.

<span class="mw-page-title-main">Sotio</span>

SOTIO Biotech is a Czech biotechnology company focused on clinical-stage research and development of innovative medicines for cancer with operations in Europe, North America, and Asia. The company has clinical programs which include a superagonist of the immuno-oncology target IL-15, a new generation of potent and stable antibody-drug conjugates (ADCs), proprietary technology designed to improve on the efficacy of CAR T therapies and a platform to streamline and enhance personalized cell therapies.

Imugene Ltd is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Imugene's unique platform technologies seeks to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Paul A. Hopper is an Australian bioentrepreneur who has been associated since 2003 with a number of biotechnology companies, most of them publicly traded.

Viralytics Ltd is an Australian biotechnology company working in the field of oncolytic viruses, that is, viruses that preferentially infect and kill cancer cells. The company's oncolytic virus product, called Cavatak, is currently in clinical trials in metastatic melanoma and other cancers. The drug was granted Orphan Drug status in advanced melanoma in December 2005.

Said Sebti (Arabic: سيد سبتي, (first name is an American cancer researcher who is Professor and Chairman of the Department of Drug Discovery at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Fl. Sebti is noted for his work to rehabilitate the 'failed' cancer drug Triciribine, now under development at the pharmaceutical company Prescient Therapeutics. Sebti is currently Chief Scientific Officer at Prescient Therapeutics.

<span class="mw-page-title-main">Triciribine</span> Chemical compound

Triciribine is a cancer drug which was first synthesized in the 1970s and studied clinically in the 1980s and 1990s without success. Following the discovery in the early 2000s that the drug would be effective against tumours with hyperactivated Akt, it is now again under consideration in a variety of cancers. As PTX-200, the drug is currently in two early stage clinical trials in breast cancer and ovarian cancer being conducted by the small molecule drug development company Prescient Therapeutics.

GEMoaB is a biopharmaceutical company based in Dresden/Germany. The company has a broad pipeline of next generation immunotherapy product candidates for the treatment of advanced blood cancers and solid tumours in pre-clinical and clinical development. The company was founded in 2011 by the two university professors Gerhard Ehninger and Michael Bachmann. It was acquired by the new company AvenCell Therapeutics in 2021.

References

  1. ↑ "Virax to Acquire Exclusive Worldwide License to Yale University Phase I/II Ready Programs in Multiple Myeloma and Breast Cancer" (PDF). asx.com.au. 17 March 2004. Archived (PDF) from the original on 4 March 2016. Retrieved 17 August 2022.
  2. ↑ "Virax Completes Acquisition of US Specialty Company and Novel Cancer Drug Candidate" (PDF). asx.com.au. 30 May 2014. Archived (PDF) from the original on 4 March 2016. Retrieved 17 August 2022.
  3. ↑ "Virax to Acquire Deep AKT Inhibitor Portfolio Already in Phase Ib/II Breast and Phase Ib Ovarian Cancer Trials" (PDF). asx.com.au. 17 October 2014. Archived (PDF) from the original on 4 March 2016. Retrieved 17 August 2022.
  4. ↑ "Prescient Completes Acquisition of AKTivate Therapeutics" (PDF). asx.com.au. 11 December 2014. Archived (PDF) from the original on 4 March 2016. Retrieved 17 August 2022.
  5. ↑ "Change of Company Name" (PDF). asx.com.au. 2 December 2014. Archived (PDF) from the original on 4 March 2016. Retrieved 16 August 2022.
  6. ↑ "Prescient Collaboration with Carina Biotech to Develop Next Generation CAR-T Therapies" (PDF). asx.com.au. 18 November 2019. Archived (PDF) from the original on 13 August 2023. Retrieved 17 August 2022.
  7. ↑ "Prescient Licenses Technologies from University of Pennsylvania and Oxford University to Create Innovative Universal CAR Platform" (PDF). asx.com.au. 26 May 2020. Archived (PDF) from the original on 17 August 2022. Retrieved 17 August 2022.
  8. 1 2 "OmniCAR: Universal CAR-T platform presentation" (PDF). asx.com.au. 26 May 2020. Archived (PDF) from the original on 17 August 2022. Retrieved 17 August 2022.
  9. ↑ Zhang, Zheng-zheng; Wang, Tian; Wang, Xiao-feng; Zhang, Yu-qing; Song, Shu-xia; Ma, Cui-qing (2022-01-01). "Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies". Pharmacological Research. 175: 106036. doi: 10.1016/j.phrs.2021.106036 . ISSN   1043-6618. PMID   34920118. S2CID   245233408.
  10. ↑ "Prescient Announces Internal OmniCAR Programs for Three Next-Gen CAR-T Therapies" (PDF). asx.com.au. 18 January 2021. Archived (PDF) from the original on 17 August 2022. Retrieved 17 August 2022.
  11. ↑ "Prescient strategic collaboration with MD Anderson Cancer Center to develop unique blood cancer binder for OmniCAR" (PDF). asx.com.au. 7 September 2022. Archived (PDF) from the original on 7 September 2022. Retrieved 7 September 2022.
  12. ↑ "Prescient signs CAR-T agreement with Peter MacCallum Cancer Centre" (PDF). asx.com.au. 10 May 2021. Archived (PDF) from the original on 22 March 2022. Retrieved 17 August 2022.
  13. ↑ "Prescient achieves key milestone by demonstrating OmniCAR's key components show minimal immunogenicity in silico" (PDF). asx.com.au. 5 July 2021. Archived (PDF) from the original on 14 November 2022. Retrieved 17 August 2022.
  14. 1 2 3 "Prescient Presents New Data Demonstrating Key OmniCAR Features for Predictable & Controllable CAR-T cell Therapy" (PDF). asx.com.au. 13 October 2021. Archived (PDF) from the original on 28 June 2022. Retrieved 17 August 2022.
  15. ↑ "Prescient Signs Manufacturing Agreement for Next Generation CAR-T Therapy OmniCAR Ahead of Clinical Trials" (PDF). asx.com.au. 16 August 2022. Archived (PDF) from the original on 17 August 2022. Retrieved 17 August 2022.
  16. ↑ "Prescient Unveils Clinic-Ready CellPryme-M Platform for Enhancing Cell Therapies" (PDF). asx.com.au. 8 June 2022. Archived (PDF) from the original on 17 August 2022. Retrieved 17 August 2022.
  17. ↑ "Unveiling CellPryme - A Novel Platform for Enhancing Cell Therapies" (PDF). asx.com.au. 8 June 2022. Archived (PDF) from the original on 17 August 2022. Retrieved 17 August 2022.
  18. ↑ "Prescient Unveils CellPryme-A: Novel Adjuvant for Enhancing Cellular Immunotherapy" (PDF). asx.com.au. 23 September 2022. Archived (PDF) from the original on 28 September 2022. Retrieved 28 September 2022.
  19. ↑ "CellPryme-A Investor Presentation" (PDF). asx.com.au. 27 September 2022. Archived (PDF) from the original on 28 September 2022. Retrieved 28 September 2022.
  20. ↑ "Prescient expands PTX-200 AML Cohort Following Additional Complete Remission" (PDF). asx.com.au. 9 May 2022. Archived (PDF) from the original on 15 November 2022. Retrieved 17 August 2022.
  21. ↑ "FDA Grants Orphan Drug Designation for PTX-200 in Acute Myeloid Leukemia" (PDF). asx.com.au. 1 May 2017. Archived (PDF) from the original on 17 August 2022. Retrieved 17 August 2022.
  22. ↑ "Prescient's PTX-200 Phase 2a trial in HER2-Negative Breast Cancer Exhibits High Overall Response Rate" (PDF). asx.com.au. 23 December 2019. Archived (PDF) from the original on 17 August 2022. Retrieved 17 August 2022.
  23. ↑ "Encouraging Interim Data from Phase 1b Ovarian Cancer Trial with PTX-200" (PDF). asx.com.au. 12 December 2019. Archived (PDF) from the original on 21 June 2022. Retrieved 17 August 2022.
  24. 1 2 "PTX-100 Trial Progresses to Expansion Cohort Following Successful Phase 1b" (PDF). asx.com.au. 27 July 2021. Archived (PDF) from the original on 15 November 2022. Retrieved 17 August 2022.
  25. ↑ "US FDA Grants Orphan Drug Designation to PTX-100 for PTCL" (PDF). asx.com.au. 15 July 2022. Archived (PDF) from the original on 19 July 2022. Retrieved 17 August 2022.
  26. ↑ "Prescient receives new US Patent for Companion Diagnostic for PTX-100" (PDF). asx.com.au. 26 October 2020. Archived (PDF) from the original on 17 August 2022. Retrieved 17 August 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.